-
-
Apixaban could soon join the anticoagulation market; Chinese herbs for flu; chronic medication and discontinuation after hospitalization; and FDA actions.
-
New emphasis on optimal medical therapy in atherosclerotic cardiovascular (CV) disease has focused attention on the short-term variability of blood pressure (BP) measurements and the difficulty this poses for the diagnosis and treatment of hypertension.
-
This paper presents data from the Nurses' Health Study. This is a large study that was begun in 1976 which surveyed nurses with initial ages between 30 and 55 and collected data on lifestyle and other risk factors and correlated these data with the development of cardiac disease.
-
In this paper, the authors present data from the Valsartan in Acute Myocardial Infarction Trial (VALIANT) on the circumstances and outcomes of cardiac arrest after myocardial infarction (MI).
-
Percutaneous transcatheter aortic valve implantation (TAVI) is an emerging technique for the treatment of aortic stenosis (AS). By this method, a bioprosthetic valve (bovine pericardium) attached to a stent can be deployed in the aortic valve position via a catheter delivery system inserted through either the femoral artery or via the apex of the left ventricle. This technique is available in Europe and is being considered by the FDA for release in the United States.
-
The benefits of cardiac rehabilitation following myocardial infarction (MI) are well known. However, whether these benefits are also seen in ambulant community-based patients who undergo percutaneous coronary intervention (PCI) is not known.
-
The use of aspirin for the primary prevention of cardiovascular (CV) disease remains controversial. In this publication, Bartolucci updates his 2006 meta-analysis by adding three new trials to the six previous ones.
-
-
FDA issues multiple drug safety alerts; ARBs and cancer risk; and FDA actions.
